Introduction
============

Clinical data suggest that male and female patients exhibit differences regarding the pharmacology and toxicity of medications[@b1-dddt-10-2917] and differ in their response to drug treatment, not only as a result of physiological differences, such as body weight, surface area, and extracellular and intracellular water, but also in terms of differences in pharmacokinetics (PK) and pharmacodynamics (PD).[@b2-dddt-10-2917]--[@b4-dddt-10-2917] It is known that sex hormones influence drug absorption, distribution, metabolism, PD, and adverse events (AEs).[@b5-dddt-10-2917] In 2001, on the basis of its Adverse Events Reporting System, the US Food and Drug Administration stated that females experience more and more serious AEs (SAEs) than males.[@b6-dddt-10-2917] It has been hypothesized that this may be due to overdosing, different PK and PD, the fact that females are more likely to report AEs than males, or that females take more medications than males. It has been shown that females use more medicines than males do and have a higher rate of chronic diseases, but they also generally pay more attention to their health and have more consciousness and care about themselves.[@b6-dddt-10-2917]

Despite the increasing evidence of physiological and pathological differences between genders, beyond those related to reproduction,[@b7-dddt-10-2917]--[@b11-dddt-10-2917] females still represent a small percentage (22%) of participants in Phase I trials which are essential to verify drug dosage, AEs, and safety.[@b12-dddt-10-2917] Medical research has been conducted for decades with a large prevalence of male participants in clinical studies, yet the findings of these studies have often been applied to both genders.[@b12-dddt-10-2917] Only with the new millennium has this changed with the European Union promoting females's participation in research projects and the World Health Organization including gender medicine in the Equity Act in order to achieve gender-appropriate care.[@b13-dddt-10-2917] However, to date, the analyses provided by the pharmaceutical industry to the regulatory authorities often do not classify safety and efficacy data by gender.

In 2013, the Italian Drug Agency (Agenzia Italiana del Farmaco) invited pharmaceutical companies to process data divided by gender during the submission of regulatory documentation, so as to highlight possible differences.[@b14-dddt-10-2917] In the same year, Novartis Italy put in place a wide gender-medicine project, called MetaGeM, which included analysis by gender of the data from nine previously conducted observational studies. These studies were performed between 2002 and 2013, and covered a range of different clinical areas, including immune-mediated disorders (psoriasis and psoriatic arthritis), transplantation medicine (liver and kidney transplants), infectious diseases (hepatitis B), and the central nervous system (Parkinson's disease and Alzheimer's disease \[AD\]). The aim of the MetaGeM project was to analyze and describe clinical outcomes, therapeutic approaches, and safety data by gender, using post hoc analyses and meta-analyses, in order to explore possible gender differences. The methodology of the MetaGeM project has been described in detail elsewhere.[@b15-dddt-10-2917] The present paper reports the results of the overall safety analysis of the MetaGeM studies, aimed at evaluating possible gender differences in the incidence and severity of AEs and the potential association between gender and safety.

Methods
=======

Seven of the nine observational studies of the MetaGeM project were included in this safety analysis on 2,612 (53.6%) males and 2,258 (46.4%) females: they are listed and briefly described in [Table 1](#t1-dddt-10-2917){ref-type="table"}. With regard to the two excluded studies, the GENDER-ATTENTION ("The female in her real dimension: effect of gender and hormonal status on adverse events' incidence in psoriatic patients treated with cyclosporine") study (Colombo et al, unpublished data, 2013a; Colombo et al, unpublished data, 2013b; Colombo et al, unpublished data, 2014a; Colombo et al, unpublished data, 2014b; Colombo et al, unpublished data, 2016) was not included because a gender-specific safety assessment was the primary objective of the study itself, while the Studio Osservazionale Italiano per la valutazione dell'insUfficienza Renale in pazienti con trapianto di Fegato (SURF) ("Italian Observational Study for the evaluation of renal insufficiency in liver transplant patients") study (Donato et al, unpublished data, 2013) was also not considered because it did not include safety data collection.

An AE was defined as any unfavorable or unintended sign, symptom, or disease that occurred from the time the signed informed consent was obtained until the end of the patient observation period. An AE was defined as a SAE if it resulted in death, was judged life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, or caused a congenital anomaly/birth defect in the child of the observed patient. In cases where such information was available, the possible relationship with therapy, as evaluated by the investigator, was reported.

Data were collected between February 2002 (first patient first visit; PSYCHAE study[@b16-dddt-10-2917],[@b17-dddt-10-2917]) and July 2013 (last patient last visit; ICEBERG study \[Rizzetto et al, unpublished data, 2011; Bandiera et al, unpublished data, 2012\]); first patient first visit and last patient last visit for each study are shown in [Table 1](#t1-dddt-10-2917){ref-type="table"}. Monitoring visits were conducted to verify whether enrollment was performed consecutively and according to inclusion/exclusion criteria. Moreover, before statistical analysis, a data cleaning process was run to check the collected data for completeness and accuracy.

Patients were considered evaluable for this analysis if they were evaluable for the individual study in which they participated and if gender was recorded in the case report form (CRF), as detailed elsewhere.[@b16-dddt-10-2917]--[@b23-dddt-10-2917]

Evaluable patients were described according to sociodemographic (such as age) and clinical (such as ongoing specific therapies) features. Moreover, male and female patients were compared with regard to the main safety variables: AE occurrence and characteristics (description, intensity, possible correlation with a drug, evolution, and therapeutic intervention, if any), and SAE occurrence and description. Comparisons were performed by Student's *t*-test, *χ*^2^ test, or Fisher's exact test as appropriate. For the post hoc analyses, all *P*-values presented are exploratory. Patients with missing data in selected parameters were not excluded from analysis, but were simply not evaluated for these parameters.

Data collection was performed for all studies through the CRF; however, not all variables of interest were present in all studies or, if present, not all had the same answer categories. For these reasons, AE CRF fields that were common to all studies were identified through a preliminary analysis, and a new variable for each outcome of interest (eg, AE description, AE intensity) was created considering the value in each study. Fields that were missing in some studies were analyzed only where present.

Different answer modalities were present in the original CRFs for AE intensity, possible correlation of AE with a drug, and AE evolution, and so recoding was performed. Briefly, the AE intensity was classified as mild, moderate, high, or not determined, as originally reported in most studies. In the EVOLUTION study, grade 1 intensity (based on Common Terminology Criteria for Adverse Events v3.0) was considered as mild, grade 2 as moderate, and grades 3--5 as high, while in the ICEBERG study (Rizzetto et al, unpublished data, 2011; Bandiera et al, unpublished data, 2012), AEs defined as severe were considered to be of high intensity. For the CETRA study, the intensity of AEs could not be analyzed because this variable was not collected on the CRF. Possible correlation with a drug was defined as present (yes), absent (no), or not determined; if changes in therapy had been introduced, these were evaluated in terms of dosage escalation or reduction, therapy discontinuation, or "other". Concerning their evolution, AEs were considered as resolved (including resolved without sequelae), unresolved, toward resolution, resolved without sequelae, or resolution unknown. SAEs were reported as death, hospitalization, disability, persistent or significant inability, life-threatening events, or not determined.

As supportive analysis, a logistic regression model was estimated to evaluate the association between gender (male, female) and outcome ("the patient had at least one AE during the study"). The model provided estimates of the odds ratios of experiencing an AE in female versus male patients. All analyses were performed with SAS v9.2 and Enterprise Guide v4.3. (SAS v9.2: Copyright © 2009 by SAS Institute Inc., Cary, NC, USA; Enterprise Guide v4.3 Copyright © 2006--2010 by SAS Institute Inc., Cary, NC, USA).

Results
=======

In total, 4,870 patients, 46% females and 54% males, were included in the analysis, as detailed in [Table 1](#t1-dddt-10-2917){ref-type="table"}. Age by gender and study is reported in [Table 2](#t2-dddt-10-2917){ref-type="table"}: overall, mean age was higher in females (61.2±18.3 years) than in males (56.3±16.6 years). Disease-specific therapies ongoing at enrollment in the studies are summarized in [Table 3](#t3-dddt-10-2917){ref-type="table"}.

Overall, 264 AEs were reported, 59.1% in males; [Table 4](#t4-dddt-10-2917){ref-type="table"} summarizes the type of AEs, according to the Medical Dictionary for Regulatory Activities (MedDRA) system organ class.

There was no significant gender difference in the percentage of patients with at least one AE (ie, patients with 1, 2, or ≥3 AEs): 3.0% for females versus 3.9% for males, *χ*^2^ test *P*≥0.05. Details about the occurrence and intensity of AEs by gender and study are reported in [Table 5](#t5-dddt-10-2917){ref-type="table"}. The results of the logistic regression model also showed no association between gender and AE occurrence: odds ratio =0.764 (females vs males), 95% confidence interval: 0.559--1.044, but a statistically significant gender difference in the percentage of drug-related AEs emerged (37.6% in females vs 20.8% in males, *χ*^2^ test *P*=0.0039). AE evolution is depicted in [Figure 1](#f1-dddt-10-2917){ref-type="fig"}. Overall, more AEs were addressed with some kind of treatment in females compared with males (78.1% vs 66.7%, *χ*^2^ *P*=0.0485).

Total SAEs were 47 (72% in males). The frequency of patients with ≥1 SAE was 0.6% in females versus 1.2% in males (*χ*^2^ test *P*=0.0246). Number and type of SAEs are detailed in [Table 6](#t6-dddt-10-2917){ref-type="table"}.

Discussion
==========

Gender-specific medicine is the study of how diseases differ between males and females in terms of prevention, clinical manifestations, therapeutic approach, outcomes and tolerability, prognosis, and psychological and social impact. There has been increasing evidence in recent years of physiological and pathological differences between the genders. Focusing on the diseases examined in the studies included in our analysis, many gender differences have been reported for patients with psoriasis and psoriatic arthritis, in terms of epidemiology,[@b24-dddt-10-2917] pattern and burden of disease,[@b25-dddt-10-2917] search for care,[@b26-dddt-10-2917] and choice of therapy;[@b27-dddt-10-2917],[@b28-dddt-10-2917] for example, peripheral joint involvement, pain, and functional impairment are more frequent for female than for male patients with psoriasis.[@b29-dddt-10-2917]--[@b32-dddt-10-2917] Moreover, the PSYCHAE study[@b16-dddt-10-2917] pointed out that the psychological status of females was also worse than that of males, independently of the severity of psoriasis. There is also an extensive literature on gender differences in AD, as recently reviewed by Li and Singh.[@b33-dddt-10-2917] Clinical studies have shown differences between males and females in specific cognitive ability domains and risk of AD at later age. Several major biological hypotheses have been postulated, such as differences in age-related sex hormone reduction (estrogens, progesterone, testosterone), impact from risks of other diseases (diabetes, depression), and age-related decline in brain volume. In Parkinson's disease as well, gender-related differences have been recognized, although these are still poorly understood. Prevalence and incidence of Parkinson's disease are significantly higher in males than in females.[@b34-dddt-10-2917],[@b35-dddt-10-2917] From a clinical point of view, females with Parkinson's disease have shown worse capacity in activities of daily living and more severity of levodopa-induced dyskinesia in several studies,[@b36-dddt-10-2917]--[@b38-dddt-10-2917] while male gender was shown to predict worse rigidity score and higher risk for sleep behavior disorder, dementia, and death.[@b37-dddt-10-2917],[@b39-dddt-10-2917]--[@b41-dddt-10-2917] A 2014 cross-sectional survey[@b42-dddt-10-2917] found that males reported a greater disease burden and greater daily levodopa equivalent doses than females. The greater burden of disease score in males was significantly associated with gender even after controlling for age and disease duration. Concerning transplants, gender-based disparities have been observed in post-liver transplantation outcomes, together with a continuous decline in the number of liver transplantations in females.[@b43-dddt-10-2917]

The effect of gender on drug tolerability has begun to raise interest only in recent years, mainly resulting in the observation that females experience more frequent and more SAEs than males, possibly due to different PK and PD, higher rates of AE reporting, or greater use of medications in females compared to males.[@b6-dddt-10-2917],[@b44-dddt-10-2917]--[@b46-dddt-10-2917] Clinical research sponsored by Novartis Italy in the past decade included several large observational studies in important medical areas, including psoriasis.[@b16-dddt-10-2917],[@b17-dddt-10-2917],[@b22-dddt-10-2917],[@b47-dddt-10-2917] Central nervous system disorders, such as Parkinson's disease and AD,[@b18-dddt-10-2917]--[@b21-dddt-10-2917] and transplantation,[@b23-dddt-10-2917] but none of those studies, except one (the aforementioned GENDER-ATTENTION study \[Colombo et al, unpublished data, 2013a; Colombo et al, unpublished data, 2013b; Colombo et al, unpublished data, 2014a; Colombo et al, unpublished data, 2014b; Colombo et al, unpublished data, 2016\]), adopted a gender-specific approach in data analysis. Based on the increasing interest in gender medicine and prompted by the large quantity of clinical data available through these large national studies, it was decided to reanalyze these data from a gender perspective (the MetaGeM project). This paper focuses on the overall safety data from seven MetaGeM studies.

The overall MetaGeM sample (N=4,870) consisted of 2,612 (53.6%) males, with females being predominant only in the two AD studies, EVOLUTION and AXEPT (59.7% and 63.6%, respectively, of those enrolled are female). This prevalence of female patients in the AD studies probably accounts for the overall higher mean age in females compared with males.

There were no significant gender differences in the frequency of patients with at least one AE (3.0% for females vs 3.9% for males, *χ*^2^ test *P*\>0.05), with 59.1% of global AEs occurring in males. Considering only those reported as drug-related AEs, the incidence was significantly higher in females, and this is consistent with several reports revealing that females are more prone to adverse drug reactions (ADRs) than males, as confirmed by the evidence that eight of ten drugs that have been dropped out from the US market were responsible for more ADRs in females than in males. Indeed, risk factors for ADRs, such as polytherapy, aging (females become generally older than males), and depression, are in general more frequent in females than in males.[@b44-dddt-10-2917]--[@b46-dddt-10-2917],[@b48-dddt-10-2917],[@b49-dddt-10-2917] Other factors hypothesized to explain why females usually report more ADRs are the fact that females have a higher prevalence of pain (headache, migraine, musculoskeletal pain) and pay greater attention to their health status. Moreover, physiological aspects, such as menstrual cycles, pregnancy, and menopause, are likely to have a relevant impact on the PK and PD of drugs.

Unexpectedly, we found that 2% of SAEs occurred in males, and the frequency of patients reporting at least one SAE was significantly higher in males, despite the older mean age of females compared with males. These results are in contrast with the large quantity of published data showing that females experience more AEs and that these are generally also more serious.[@b6-dddt-10-2917],[@b30-dddt-10-2917]--[@b32-dddt-10-2917] However, it has to be considered that the overall patient population was fairly unbalanced by the CETRA study on renal transplantation (inclusion criteria: age ≥18 years, renal allograft functioning for at least 6 months, and serum creatinine level \<2.5 mg/dL), which included 64% male patients and accounted for 77% of total SAEs (36 of 47). This may be reasonably explained by the fact that the CETRA patients were transplanted patients, frequently hospitalized for transplant-related events. For these reasons, in order to have a more homogeneous population, we repeated the analysis excluding CETRA patients. This analysis showed no significant difference between the genders in terms of SAEs (0.2% of females vs 0.4% of males had at least one SAE; *χ*^2^ test, *P*\>0.05).

We had no adequate information about the degree of disease severity in the patients considered for this analysis and therefore were unable to analyze for possible correlations between severity of disease and incidence of AE; however, we hypothesized that the type and number of therapies administered could mirror the severity of the disease, at least for the DEEP study (Parkinson's disease) and the PSYCHAE and SYNERGY studies (psoriasis ± psoriatic arthritis). Following specific analyses, we found no correlations between the incidence of AEs and the number of drugs administered to patients (1--2 and ≥3) in the DEEP study, or the type of therapy (topical or systemic) in the other two studies in psoriasis. This seems to confirm that the observed gender differences were not biased by the severity of the disease.

Limitations
===========

Our study has some limitations. As a post hoc analysis, it was not originally designed to assess gender differences in patients' safety profile, and statistical analysis was mainly descriptive with only explorative *P*-values. Moreover, owing to the inclusion of several studies, large differences in patient population, study design, and ongoing treatments have to be taken into account. For this reason, a common approach for data cleaning, recoding, and statistical analysis was followed. Finally, one single study, CETRA, which studied the quite complex and serious clinical condition of renal transplantation, accounted for the majority of AEs (183/264) and SAEs (36/47), and this may have strongly affected the results of our analysis.

Conclusion
==========

This safety analysis on a large sample of almost 5000 patients affected with different diseases and treated with a wide range of different drugs provides a useful overview, within the considered disease areas, of possible gender differences in drug tolerability, which may be helpful in more accurately designing future clinical trials from a gender-specific perspective.
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![Evolution of AEs by gender.\
**Note:** Percentages calculated over total number of AEs during observation with available data on evolution (N=256).\
**Abbreviation:** AEs, adverse events.](dddt-10-2917Fig1){#f1-dddt-10-2917}

###### 

MetaGeM observational studies and patients included in the analysis

  Area (disease)                Study                                                                                                                                                                                                                                                     Patient population and study objectives                                                                                                                                                                                 Ongoing specific therapies                                                                                                                                                                                                           FPFV             LPLV             Females     Males      Total                  
  ----------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ ---------------- ---------------- ----------- ---------- ----------- ---------- -----------
  **CNS**                       DEEP[@b18-dddt-10-2917],[@b19-dddt-10-2917] (Early detection of wearing off in Parkinson's disease)                                                                                                                                                       Assessment of wearing off in patients with Parkinson's disease under treatment with levodopa and/or dopamine agonists without dementia                                                                                  Levodopa and/or dopamine agonists                                                                                                                                                                                                    March 2010       November 2010    236         38.3       381         61.8       617
  **CNS**                       EVOLUTION[@b20-dddt-10-2917] (Behavioral symptoms in AD: evaluation of patients treated with ChEI)                                                                                                                                                        Evaluation of changes in cognitive and affective domain severity in mild-to-moderate AD patients undergoing a switch of ChEI for lack or loss of efficacy and/or tolerability/compliance                                Switch from one ChEI to another after ≥6 months, due to lack or loss of efficacy (reduction of ≥2 points of MMSE score in the last 6 months) and/or reduced compliance (due to side effects or nonadherence to recommended dosing)   April 2010       September 2011   379         59.7       256         40.3       635
  **CNS**                       AXEPT[@b21-dddt-10-2917] (AD: examination of patient compliance and caregiver satisfaction)                                                                                                                                                               Comparing compliance to treatment of community-dwelling patients with mild-to-moderate AD treated with transdermal or oral drugs and caregiver satisfaction in a real clinical setting                                  ChEIs (oral or transdermal) or memantine in monotherapy                                                                                                                                                                              September 2010   January 2011     544         63.6       311         36.4       855
  **Infectious diseases**       ICEBERG (Natural history of chronic hepatitis B virus infection: an observational study on asymptomatic HBsAg carriers)[a](#tfn2-dddt-10-2917){ref-type="table-fn"}                                                                                       Evaluation of natural history of disease in asymptomatic, untreated HBsAg carriers                                                                                                                                      NA                                                                                                                                                                                                                                   December 2008    July 2013        377         42.1       518         57.9       895
  **Dermatology (psoriasis)**   PSYCHAE[@b16-dddt-10-2917],[@b22-dddt-10-2917] (Psoriasis: survey for the control of anxiety and depression)                                                                                                                                              Assessing the prevalence and evolution of psychological distress in a large series of Italian patients with psoriasis followed at dermatological centers                                                                Phototherapy, systemic medications, non-pharmacological therapy, topical treatments                                                                                                                                                  February 2002    May 2004         309         39.3       477         60.7       786
  **Dermatology (psoriasis)**   SYNERGY[@b17-dddt-10-2917] (Observational study of infectious events in psoriasis complicated by active psoriatic arthritis)                                                                                                                              Evaluation of infectious events in patients with psoriasis and psoriatic arthritis receiving systemic immunosuppressive therapy, including CsA                                                                          CsA ± other immune-suppressants                                                                                                                                                                                                      March 2010       January 2012     104         46.2       121         53.8       225
  **Dermatology (psoriasis)**   GENDER-ATTENTION[b](#tfn3-dddt-10-2917){ref-type="table-fn"},[\*](#tfn1-dddt-10-2917){ref-type="table-fn"} (The female in her real dimension: effect of gender and hormonal status on adverse events' incidence in psoriatic patients treated with CsA)   Evaluation of the differences in side effects' incidence rate (as patient leaflet) between females (stratified by fertile/menopausal status) and age-matched males in patients with plaque psoriasis treated with CsA                                                                                                                                                                                                                                                                                                                        
  **Transplants**               CETRA[@b23-dddt-10-2917] (Complications related to gastro-enteric symptoms in renal transplant patients) (Ponticelli)                                                                                                                                     Evaluation of the prevalence of gastrointestinal symptoms in patients with functioning, stable renal transplant and no underlying diseases that could cause gastrointestinal symptoms                                   CsA + azathioprine + CS CsA + MMF CsA + MMF + CS CsA + CS Tacrolimus + MMF + CS Tacrolimus + CS                                                                                                                                      June 2006        April 2008       309         36.1       548         63.9       857
  **Transplants**               SURF[\*](#tfn1-dddt-10-2917){ref-type="table-fn"} (Italian Observational Study for the evaluation of Renal Insufficiency in liver transplant patients) (Donato et al, unpublished data, 2013)                                                             Evaluation of the proportion of patients with eGFR \<60 mL/min/1.73 m^2^ at inclusion visit and 12 months after the inclusion visit                                                                                                                                                                                                                                                                                                                                                                                                          
                                Total evaluable patients                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 **2,258**   **46.4**   **2,612**   **53.6**   **4,870**

**Notes:**

Study not considered in the present analysis.

Rizzetto et al, unpublished data, 2011; Bandiera et al, unpublished data, 2012.

Colombo et al, unpublished data, 2013a; Colombo et al, unpublished data, 2013b; Colombo et al, unpublished data, 2014a; Colombo et al, unpublished data, 2014b; Colombo et al, unpublished data, 2016.

**Abbreviations:** AD, Alzheimer's disease; ChEI, cholinesterase inhibitors; CNS, central nervous system; CsA, cyclosporine; CS, corticosteroids; eGFR, epidermal growth factor receptor; FPFV, first patient first visit; LPLV, last patient last visit; MMF, mycophenolate mofetil; HBsAg, Hepatitis B surface antigen; MMSE, Mini Mental State Examination; NA, not available.

###### 

Demographic characteristics of patients

  Study                                                                      Mean age (years)   Standard deviation   ≥50 years N (%)
  -------------------------------------------------------------------------- ------------------ -------------------- -----------------
  PSYCHAE[@b16-dddt-10-2917],[@b22-dddt-10-2917]                                                                     
   Females                                                                   43.7               13.0                 123 (39.8)
   Males                                                                     45.3               12.1                 184 (38.6)
   Total                                                                     44.7               12.5                 307 (39.1)
  DEEP[@b18-dddt-10-2917],[@b19-dddt-10-2917]                                                                        
   Females                                                                   67.0               8.9                  228 (96.6)
   Males                                                                     66.6               9.4                  362 (95.0)
   Total                                                                     66.8               9.2                  590 (95.6)
  EVOLUTION[@b20-dddt-10-2917][a](#tfn6-dddt-10-2917){ref-type="table-fn"}                                           
   Females                                                                   77.2               7.1                  378 (99.7)
   Males                                                                     76.0               6.9                  256 (100.0)
   Total                                                                     76.7               7.0                  634 (99.8)
  AXEPT[@b21-dddt-10-2917],[b](#tfn7-dddt-10-2917){ref-type="table-fn"}                                              
   Females                                                                   78.2               6.4                  544 (100.0)
   Males                                                                     76.9               6.6                  311 (100.0)
   Total                                                                     77.7               6.5                  855 (100.0)
  ICEBERG[d](#tfn9-dddt-10-2917){ref-type="table-fn"}                                                                
   Females                                                                   44.9               12.9                 158 (41.9)
   Males                                                                     45.4               11.6                 208 (40.2)
   Total                                                                     45.2               12.2                 366 (40.9)
  SYNERGY[@b17-dddt-10-2917]                                                                                         
   Females                                                                   50.8               12.5                 54 (51.9)
   Males                                                                     48.9               12.8                 57 (47.1)
   Total                                                                     49.8               12.7                 111 (49.3)
  CETRA[@b23-dddt-10-2917]                                                                                           
   Females                                                                   48.1               11.6                 146 (47.2)
   Males                                                                     49.6               12.2                 287 (52.4)
   Total                                                                     49.1               12.0                 433 (50.5)
  **Total evaluable patients**[c](#tfn8-dddt-10-2917){ref-type="table-fn"}                                           
   Females                                                                   61.2               18.3                 1,631 (72.2)
   Males                                                                     56.3               16.6                 1,665 (63.7)
   Total                                                                     58.6               17.6                 3,296 (67.7)

**Notes:** Student's *t*-test *P*-values (males versus females):

0.0427;

0.0045;

0.0001.

Rizzetto et al, unpublished data, 2011; Bandiera et al, unpublished data, 2012. Percentages calculated for the total number of evaluable patients.

###### 

Specific medications taken at inclusion in the study

  Study                                            Medications                                                         Females N (%)   Males N (%)   Total evaluable patients, N (%)
  ------------------------------------------------ ------------------------------------------------------------------- --------------- ------------- ---------------------------------
  DEEP[@b18-dddt-10-2917],[@b19-dddt-10-2917]      DA                                                                  11 (4.7)        15 (3.9)      26 (4.2)
                                                   DA + MAO-B inhibitors                                               17 (7.2)        36 (9.4)      53 (8.6)
                                                   Levodopa                                                            29 (12.3)       35 (9.2)      64 (10.4)
                                                   Levodopa + DA                                                       59 (25.0)       77 (20.2)     136 (22.0)
                                                   Levodopa + DA + COMT inhibitors                                     41 (17.4)       73 (19.2)     114 (18.5)
                                                   Levodopa + DA + MAO-B inhibitors                                    28 (11.9)       56 (14.7)     84 (13.6)
                                                   Levodopa + DA + MAO-B inhibitors + COMT inhibitors                  24 (10.2)       28 (7.3)      52 (8.4)
                                                   Levodopa + COMT inhibitors                                          12 (5.1)        24 (6.3)      36 (5.8)
                                                   Levodopa + MAO-B inhibitors                                         13 (5.5)        30 (7.9)      43 (7.0)
                                                   Levodopa + MAO-B inhibitors + COMT inhibitors                       2 (0.8)         7 (1.8)       9 (1.5)
                                                   Total evaluable patients                                            236 (100.0)     381 (100.0)   617 (100.0)
  EVOLUTION[@b20-dddt-10-2917]                     Donepezil (oral)                                                    264 (69.7)      178 (69.5)    442 (69.6)
                                                   Galantamine (oral)                                                  33 (8.7)        18 (7.0)      51 (8.0)
                                                   Rivastigmine (patch)                                                52 (13.7)       24 (9.4)      76 (12.0)
                                                   Rivastigmine (oral)                                                 30 (7.9)        36 (14.1)     66 (10.4)
                                                   Total evaluable patients                                            379 (100.0)     256 (100.0)   635 (100.0)
  AXEPT[@b21-dddt-10-2917]                         Donepezil (oral)                                                    142 (26.1)      78 (25.1)     220 (25.7)
                                                   Galantamine (oral)                                                  21 (3.9)        12 (3.9)      33 (3.9)
                                                   Memantine (oral)                                                    107 (19.7)      70 (22.5)     177 (20.7)
                                                   Rivastigmine (patch)                                                253 (46.5)      141 (45.3)    394 (46.1)
                                                   Rivastigmine (oral)                                                 21 (3.9)        10 (3.2)      31 (3.6)
                                                   Total evaluable patients                                            544 (100.0)     311 (100.0)   855 (100.0)
  CETRA[@b23-dddt-10-2917]                         CsA + AZA + steroids                                                25 (8.1)        29 (5.3)      54 (6.3)
                                                   CsA + MMF                                                           21 (6.8)        33 (6.0)      54 (6.3)
                                                   CsA + MMF + steroids                                                42 (13.6)       95 (17.3)     137 (16.0)
                                                   CsA + steroids                                                      31 (10.0)       49 (8.9)      80 (9.3)
                                                   Tacrolimus + MMF + steroids                                         46 (14.9)       75 (13.7)     121 (14.1)
                                                   Tacrolimus + steroids                                               20 (6.5)        33 (6.0)      53 (6.2)
                                                   Total evaluable patients                                            309 (100.0)     548 (100.0)   857 (100.0)
  PSYCHAE[@b16-dddt-10-2917],[@b22-dddt-10-2917]   Phototherapy                                                        88 (28.5)       178 (37.3)    266 (33.8)
                                                   Systemic drug therapy                                               111 (35.9)      192 (40.3)    303 (38.5)
                                                   Non-pharmacologic therapy                                           83 (26.9)       131 (27.5)    214 (27.2)
                                                   Topical therapy                                                     224 (72.5)      357 (74.8)    581 (73.9)
                                                   Total evaluable patients                                            309 (100.0)     477 (100.0)   786 (100.0)
  SYNERGY[@b17-dddt-10-2917]                       Local infiltrations ≤12 months before baseline                      1 (1.0)         4 (3.3)       5 (2.2)
                                                   Systemic therapy for psoriasis and PsA ≤12 months before baseline   104 (100.0)     120 (99.2)    224 (99.6)
                                                   Topical therapy for psoriasis and PsA ≤12 months before baseline    79 (76.0)       96 (79.3)     175 (77.8)
                                                   Total evaluable patients                                            104 (100.0)     121 (100.0)   225 (100.0)

**Abbreviations:** AZA, azathioprine; CsA, cyclosporine; COMT, catechol O-methyltransferase; DA, dopamine; MAO, monoamino-oxidase; MMF, mycophenolate mofetil; PsA, psoriatic arthritis; MAO-B, monoamine oxidase-B.

###### 

AEs according to system organ class (MedDRA)

  System organ class MedDRA                              Total   \%
  ------------------------------------------------------ ------- ------
  Infections and infestations                            48      18.2
  Gastrointestinal disorders                             27      10.2
  General disorders and administration site conditions   21      8.0
  Musculoskeletal and connective tissue disorders        17      6.4
  Renal and urinary disorders                            17      6.4
  Skin and subcutaneous tissue disorders                 14      5.3
  Metabolism and nutrition disorders                     12      4.5
  Nervous system disorders                               11      4.2
  Respiratory, thoracic and mediastinal disorders        10      3.8
  Investigations                                         10      3.8
  Injury, poisoning, and procedural complications        8       3.0
  Hepatobiliary disorders                                7       2.7
  Immune system disorders                                7       2.7
  Blood and lymphatic system disorders                   7       2.7
  Psychiatric disorders                                  7       2.7
  Neoplasms benign, malignant, and unspecified           6       2.3
  Reproductive system and breast disorders               5       1.9
  Cardiac disorders                                      5       1.9
  Vascular disorders                                     5       1.9
  Eye disorders                                          3       1.1
  Surgical and medical procedures                        3       1.1
  SOC not attributed                                     14      5.3
  Total number of occurred AEs                           264     100

**Abbreviations:** AEs, adverse events; MedDRA, Medical Dictionary for Regulatory Activities; SOC, system organ class.

###### 

Occurrence of AEs during the study

  Study                                                  Patients with 1 AE N (%)   Patients with 2 AEs N (%)   Patients with ≥3 AEs N (%)   Total AEs N   Mild intensity AEs, N   Moderate intensity AEs, N   High intensity AEs, N
  ------------------------------------------------------ -------------------------- --------------------------- ---------------------------- ------------- ----------------------- --------------------------- -----------------------
  PSYCHAE[@b16-dddt-10-2917],[@b22-dddt-10-2917]                                                                                                                                                               
   Females                                               2 (0.6)                    0 (0)                       0 (0)                        2             0                       1                           0
   Males                                                 3 (0.6)                    1 (0.2)                     0 (0)                        5             2                       1                           1
   Total                                                 5 (0.6)                    1 (0.1)                     0 (0)                        7                                                                 
  DEEP[@b18-dddt-10-2917],[@b19-dddt-10-2917]                                                                                                                                                                  
   Females                                               1 (0.4)                    1 (0.4)                     0 (0)                        3             1                       2                           0
   Males                                                 3 (0.4)                    0 (0)                       0 (0)                        3             2                       1                           0
   Total                                                 4 (0.6)                    1 (0.2)                     0 (0)                        6                                                                 
  EVOLUTION[@b20-dddt-10-2917]                                                                                                                                                                                 
   Females                                               12 (3.2)                   0 (0)                       3 (0.8)                      24            12                      6                           6
   Males                                                 10 (3.9)                   1 (0.4)                     0 (0)                        12            5                       3                           2
   Total                                                 22 (3.5)                   1 (0.2)                     3 (0.5)                      36                                                                
  AXEPT[@b21-dddt-10-2917]                                                                                                                                                                                     
   Females                                               1 (0.2)                    0 (0)                       0 (0)                        1             0                       0                           0
   Males                                                 0 (0)                      1 (0.3)                     0 (0)                        2             2                       0                           0
   Total                                                 1 (0.1)                    1 (0.1)                     0 (0)                        3                                                                 
  ICEBERG[a](#tfn13-dddt-10-2917){ref-type="table-fn"}                                                                                                                                                         
   Females                                               3 (0.8)                    0 (0)                       0 (0)                        3             2                       0                           1
   Males                                                 6 (1.2)                    1 (0.2)                     0 (0)                        8             2                       1                           5
   Total                                                 9 (1.0)                    1 (0.1)                     0 (0)                        11                                                                
  SYNERGY[@b17-dddt-10-2917]                                                                                                                                                                                   
   Females                                               7 (6.7)                    0 (0)                       0 (0)                        7             2                       4                           0
   Males                                                 5 (4.1)                    3 (2.5)                     0 (0)                        11            5                       6                           0
   Total                                                 12 (5.3)                   3 (1.3)                     0 (0)                        18                                                                
  CETRA[@b23-dddt-10-2917]                                                                                                                                                                                     
   Females                                               17 (5.5)                   15 (4.9)                    6 (1.9)                      68            ND                      ND                          ND
   Males                                                 44 (8.0)                   8 (1.5)                     16 (2.9)                     115           ND                      ND                          ND
   Total                                                 61 (7.1)                   23 (2.7)                    22 (2.6)                     183                                                               
  Total evaluable patients                                                                                                                                                                                     
   Females                                               43 (1.9)                   16 (0.7)                    9 (0.4)                      108                                                               
   Males                                                 71 (2.7)                   15 (0.6)                    16 (0.6)                     156                                                               
   Total                                                 114 (2.3)                  31 (0.6)                    25 (0.5)                     264                                                               

**Notes:** Percentages calculated over total number of evaluable patients.

Rizzetto et al, unpublished data, 2011; Bandiera et al, unpublished data, 2012.

**Abbreviations:** AE, adverse event; ND, not determined.

###### 

Serious adverse events (SAEs) occurred during study

  Study                                                  Patients with ≥1 SAE during in the study                             Females N (%)   Males N (%)                                             Total evaluable patients, N (%)
  ------------------------------------------------------ -------------------------------------------------------------------- --------------- ------------------------------------------------------- ---------------------------------
  DEEP[@b18-dddt-10-2917],[@b19-dddt-10-2917]            No SAE                                                               236 (100.0)     381 (100.0)                                             617 (100.0)
                                                         Total evaluable patients                                             236 (100.0)     381 (100.0)                                             617 (100.0)
  EVOLUTION[@b20-dddt-10-2917]                           No SAE                                                               378 (99.7)      253 (98.8)                                              631 (99.4)
                                                         ≥1 SAE                                                               1 (0.3)         3 (1.2)                                                 4 (0.6)
                                                         Total evaluable patients                                             379 (100.0)     256 (100.0)                                             635 (100.0)
  AXEPT[@b21-dddt-10-2917]                               No SAE                                                               544 (100.0)     311 (100.0)                                             855 (100.0)
                                                         Total evaluable patients                                             544 (100.0)     311 (100.0)                                             855 (100.0)
  CETRA[@b23-dddt-10-2917]                               No SAE                                                               299 (96.8)      526 (96.0)                                              825 (96.3)
                                                         ≥1 SAE                                                               10 (3.2)        22 (4.0)                                                32 (3.7)
                                                         Total evaluable patients                                             309 (100.0)     548 (100.0)                                             857 (100.0)
  PSYCHAE[@b16-dddt-10-2917],[@b22-dddt-10-2917]         No SAE                                                               309 (100.0)     477 (100.0)                                             786 (100.0)
                                                         Total evaluable patients                                             309 (100.0)     477 (100.0)                                             786 (100.0)
  SYNERGY[@b17-dddt-10-2917]                             No SAE                                                               104 (100.0)     120 (99.2)                                              224 (99.6)
                                                         ≥1 SAE                                                               0 (0)           1 (0.8)                                                 1 (0.4)
                                                         Total evaluable patients                                             104 (100.0)     121 (100.0)                                             225 (100.0)
  ICEBERG[d](#tfn18-dddt-10-2917){ref-type="table-fn"}   No SAE                                                               375 (99.5)      513 (99.0)                                              888 (99.2)
                                                         ≥1 SAE                                                               2 (0.5)         5 (1.0)                                                 7 (0.8)
                                                         Total evaluable patients                                             377 (100.0)     518 (100.0)                                             895 (100.0)
                                                         Total pts with ≥1 SAE[a](#tfn15-dddt-10-2917){ref-type="table-fn"}   13 (0.6)        31 (1.2)[b](#tfn16-dddt-10-2917){ref-type="table-fn"}   44
                                                         Total SAE                                                            13 (28)         34 (72)[c](#tfn17-dddt-10-2917){ref-type="table-fn"}    47
                                                         Deaths                                                               0               2                                                       2
                                                         Persistent or significant disability or inability                    0               2                                                       2
                                                         Hospitalizations                                                     13              27                                                      40
                                                         Life-threatening events                                              0               3                                                       3
                                                         Total evaluable patients                                             2,258 (100.0)   2,612 (100.0)                                           4,870 (100.0)

**Notes:**

*χ*^2^ test, *P*=0.0246.

Percentages calculated for the total number of evaluable patients.

Percentages calculated for the total number of SAEs.

Rizzetto et al, unpublished data, 2011; Bandiera et al, unpublished data, 2012.

**Abbreviation:** pts, patients.
